ArticleMolecular neurodegeneration2026
The molecular fidelity of Aβ pathology in 5xFAD and App
Article in Molecular neurodegeneration, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Animal models, particularly mouse models, are indispensable for understanding the pathogenic mechanisms and developing therapeutic and diagnostic drugs for Alzheimer’s diseases (AD). While most AD mouse models aim to mimic amyloid-β (Aβ) pathology in their brains, previous research has demonstrated that not all models succeed in reproducing Aβ fibril structures observed in the brains of AD patients. In this study, we determined cryo-electron microscopy (cryo-EM) structures of Aβ fibrils extracted from the brains of two AD models, 5xFAD and AppNL−FPsen1P117L. The former represents one of the most widely used transgenic AD models, while the latter is the third-generation knock-in model designed to address the issues arising from App overexpression in conventional models. Our results revealed that fibrils from the 5xFAD mouse exhibit a structure nearly identical to human Type II Aβ fibrils found in AD patients, whereas the AppNL−FPsen1P117L mouse predominantly possesses Type II Aβ fibrils but also contains another Aβ fibril species. A subtle discrepancy in main chain arrangement at the position of Val36 was noted among all reported human and mouse Type II structures, potentially originating from variations in the brain microenvironment between human and mice. In conclusion, our findings validated the replication of Aβ pathology in 5xFAD and AppNL−FPsen1P117L mice and provide additional options for selecting appropriate animal models in studies necessitating molecular-level replication of Aβ structures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.